• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

MAUDE Adverse Event Report: BARD PERIPHERAL VASCULAR, INC. ULTRASCORE FOCUSED FORCE PTA BALLOON

  • Print
  • Share
  • E-mail
-
Super Search Devices@FDA
510(k) | DeNovo | Registration & Listing | Adverse Events | Recalls | PMA | HDE | Classification | Standards
CFR Title 21 | Radiation-Emitting Products | X-Ray Assembler | Medsun Reports | CLIA | TPLC
 

BARD PERIPHERAL VASCULAR, INC. ULTRASCORE FOCUSED FORCE PTA BALLOON Back to Search Results
Model Number US3513054
Medical Device Problem Code Adverse Event Without Identified Device or Use Problem (2993)
Health Effect - Clinical Codes Stenosis (2263); Vascular Dissection (3160)
Date of Event 12/12/2018
Type of Reportable Event Serious Injury
Additional Manufacturer Narrative
As the lot number for the device was provided, a manufacturing review will be performed.The sample was not returned to the manufacturer for inspection/evaluation.Therefore, the investigation of the reported event is inconclusive.Based upon the available information, the definitive root cause for this event is unknown.The instructions for use (ifu) is adequate for the reported device/patient code(s) and provides general instructions for use, as well as warnings, precautions and potential complications associated with the device.Upon receipt of new or additional information, a follow-up report will be submitted as applicable.
 
Event or Problem Description
It was reported through the results of a clinical trial, that during an angioplasty procedure with a focused force percutaneous transluminal angioplasty (pta) balloon dilatation catheter, vessel dissection was identified in the superficial femoral artery.It was further reported a bare metal stent was placed at the targeted lesion.Patient was discharged one day post index procedure.
 
Event or Problem Description
It was reported through the results of a clinical trial, that during an angioplasty procedure with a focused force percutaneous transluminal angioplasty (pta) balloon dilatation catheter, vessel dissection was identified in the superficial femoral artery.It was further reported a bare metal stent was placed at the targeted lesion.Patient was discharged one day post index procedure.New information: it was reported that approximately 6 months post index procedure, target lesion stenosis was allegedly identified via imaging.It was further reported that re-intervention was performed with successful result.
 
Additional Manufacturer Narrative
Manufacturing review: a lot history review was conducted and it was determined that a device history record (dhr) review was not required.Investigation summary: the investigation is inconclusive, as no objective evidence has been provided to confirm any alleged deficiency with the device.Based upon the available information, the definitive root cause is unknown.Label review: the review of the ifu (instructions for use), indications, warnings, precautions, cautions, possible complications, and contraindications showed that the product labeling is adequate.Additional narrative: date received by mfr; adverse event; description of event or problem.Mfr site, mfr name, city & state.
 
Additional Manufacturer Narrative
H10: manufacturing review: a lot history review was conducted and it was determined that a device history record (dhr) review was not required.Investigation summary: the investigation is inconclusive, as no objective evidence has been provided to confirm any alleged deficiency with the device.Based upon the available information, the definitive root cause is unknown.Label review: the review of the ifu (instructions for use), indications, warnings, precautions, cautions, possible complications, and contraindications showed that the product labeling is adequate.H10: b6, b7, g4 h11:section a through f - the information provided by bd represents all of the known information at this time.Despite good faith efforts to obtain additional information, the complainant / reporter was unable or unwilling to provide any further patient, product, or procedural details to bd.
 
Event or Problem Description
It was reported through the results of a clinical trial, that during an angioplasty procedure with a focused force percutaneous transluminal angioplasty (pta) balloon dilatation catheter, vessel dissection was identified in the superficial femoral artery.It was further reported a bare metal stent was placed at the targeted lesion.Patient was discharged one day post index procedure.New information: it was reported that approximately 5 months post index procedure, target lesion stenosis was allegedly identified via imaging.No re-intervention was performed.New information: it was reported that approximately 6 months post index procedure, target lesion stenosis was allegedly identified via imaging.It was further reported that re-intervention was performed with successful result.
 
Search Alerts/Recalls

  New Search  |  Submit an Adverse Event Report

Brand Name
ULTRASCORE FOCUSED FORCE PTA BALLOON
Common Device Name
FOCUSED FORCE PTA BALLOON
Manufacturer (Section D)
BARD PERIPHERAL VASCULAR, INC.
1625 w 3rd st.
tempe AZ 85281
MDR Report Key8384086
Report Number2020394-2019-00161
Device Sequence Number19330493
Product Code PNO
UDI-Device Identifier00801741116742
UDI-Public(01)00801741116742
Combination Product (Y/N)N
Initial Reporter StateMI
Initial Reporter CountryUS
PMA/510(K) Number
K172571
Number of Events Summarized1
Summary Report (Y/N)N
Reporter Type Manufacturer
Report Source company representative,study
Initial Reporter Occupation Physician
Type of Report Initial,Followup,Followup
Report Date (Section B) 01/02/2020
1 Device was Involved in the Event
1 Patient was Involved in the Event
Is this an Adverse Event Report? Yes
Is this a Product Problem Report? Yes
Operator of Device Health Professional
Device Model NumberUS3513054
Device Catalogue NumberUS3513054
Device Lot NumberGFCV2112
Was Device Available for Evaluation? No
Initial Date Received by Manufacturer 02/14/2019
Supplement Date Received by Manufacturer12/09/2019
12/26/2019
Initial Report FDA Received Date03/01/2019
Supplement Report FDA Received Date12/10/2019
01/02/2020
Is This a Single-Use Device that was
Reprocessed and Reused on a Patient? (Y/N)
No
Patient Sequence Number1
Concomitant Medical Products
and Therapy/Usage Dates
ASPIRINCLOPIDOGREL; ASPIRINCLOPIDOGREL; ASPIRINCLOPIDOGREL; ASPIRINCLOPIDOGREL
Outcome Attributed to Adverse Event Other;
Patient Age58 YR
Patient Weight85
-
-